Global Oncology Biosimilars Market Size study, By Indication (Atopic Dermatitis, Postoperative Immunosuppression, Ulcerative Colitis, Psoriasis, Keratoconjunctivitis, Others), By Drug Class (Cyclosporine, Tacrolimus, Pimecrolimus, Others), By Route of Adm

Global Oncology Biosimilars Market Size study, By Indication (Atopic Dermatitis, Postoperative Immunosuppression, Ulcerative Colitis, Psoriasis, Keratoconjunctivitis, Others), By Drug Class (Cyclosporine, Tacrolimus, Pimecrolimus, Others), By Route of Administration (Oral, Topical, Parenteral), By End-Users (Hospitals, Specialty Clinics, Homecare, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), and Regional Forecasts 2022-2028

Global Oncology Biosimilars Market is valued approximately USD XX million in 2021 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2022-2028. Oncology Biosimilars can be defined as a version of a known and proven biologic drug. These drugs are made from living things such as cells, tissues, or proteins. Biosimilars are more affordable alternatives to similar other drugs. Also, biosimilar offers similar safety and toxicity profile. Growing prevalence of cancer worldwide and increasing demand for biosimilar drugs due to affordability as well as recent partnerships and product launches from leading players are key drivers for growth of Oncology Biosimilars Market. For instance, according to World Cancer Research Fund – in 2020, around 18.1 million cancer cases were reported globally. Around 9.3 million cases were in men and 8.8 million in women. Further, Breast and lung cancers were most prevalent type of cancers worldwide, contributing 12.5% and 12.2% of all cancer cases reported in 2020. Moreover, in March 2019, the United States (U.S.) Food and Drug Administration (FDA) has approved new biosimilar from Pfizer Inc. named TRAZIMERA (trastuzumab-qyyp). This new drug is a biosimilar to Herceptin (trastuzumab). This new drug is intended for the treatment of breast cancer and Esophageal cancer. Further, in March 2022, Cipla Medpro, a wholly owned subsidiary of Cipla Limited, India entered in a partnership agreement with Madrid, Spain based mAbxience. Under this partnership both the companies would work towards bringing oncology and respiratory-related biosimilars to South Africa region. Also, growing spending on pharmaceuticals research and rising healthcare infrastructure in emerging economies are anticipated to act as a catalyzing factor for the market demand during the forecast period. However, high cost associated with the drug development & distribution and complex process of drug development and approvals impede the growth of the market over the forecast period of 2022-2028.

The key regions considered for the global Oncology Biosimilars Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to rising R&D activities and increasing prevalence of cancer as well as presence of leading market players. Whereas, Asia Pacific is anticipated to exhibit a significant growth rate over the forecast period 2022-2028. Factors such as growing number of pharmaceutical contract manufacturers and rising healthcare spending in the region, would create lucrative growth prospects for the Oncology Biosimilars Market across the Asia Pacific region.

Major market players included in this report are:
Pfizer Inc. (U.S.)
GlaxoSmithKline plc (U.K.)
Novartis AG (Switzerland)
Mylan N.V. (U.S.)
Teva Pharmaceutical Industries Ltd.(Israel)
Sanofi (France)
F. Hoffmann-La Roche Ltd. (Switzerland)
Zydus Cadila (India)
Lupin (India)
Amneal Pharmaceuticals LLC. (U.S.)


The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Indication
Breast Cancer
Lung Cancer
Colorectal Cancer
Cervical Cancer
Blood Cancer
Others
By Drug Class
Monoclonal Antibodies
Granulocyte Colony-Stimulating Factor
Others
By Route of Administration
Intravenous
Subcutaneous
Others

By End-Users
Hospitals
Specialty Clinics
Homecare
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Oncology Biosimilars Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors



Companies Mentioned

Pfizer Inc. (U.S.)
GlaxoSmithKline plc (U.K.)
Novartis AG (Switzerland)
Mylan N.V. (U.S.)
Teva Pharmaceutical Industries Ltd.(Israel)
Sanofi (France)
F. Hoffmann-La Roche Ltd. (Switzerland)
Zydus Cadila (India)
Lupin (India)
Amneal Pharmaceuticals LLC. (U.S.)

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.